In turn, this could adversely impact OS outcomes as noted in surgical series where less tumor infiltration with CD8+ T cells is associated with poorer OS48,49 and reduce the effectiveness of future potential immunotherapies that rely on the presence of a pool of healthy lymphocytes for activation and tumor homing50. The gene discussed is CD8A; the disease is neoplasm.